Replies to post #777511 on NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Great question Jesster, and you’re exactly right to ask it.

The answer is: not just glioblastoma.

Under both the MHRA Specials framework and NHS Individual Funding Request (IFR) guidance, patient-specific ATMPs like DCVax-L can be made available for any cancer type, not just GBM, as long as:


• It’s prescribed by a clinician for a named patient
• There’s a belief the patient may benefit
• And it’s manufactured under a licensed Control Site (per SI 2025 No. 87)

This is verifiable in both NHS IFR policy and MHRA guidance, there’s no cancer-type restriction. IFRs are routinely granted for rare, aggressive, or treatment-resistant solid tumors when the physician justifies it.

And yes, under SI 87, all the booster agents apply, including:

• Poly-ICLC (Hiltonol)
• G100 (TLR4)
• R848 (TLR7/8, topical)
• V937 (oncolytic virus, Merck)
• IFN-?
• Decoy10/20 (Indaptus)
• CTLA-4 or PD-1 checkpoint inhibitors

All of these are integrated into the Bosch Booster Matrix and can be deployed under the Specials framework as part of a patient-matched immune strategy, no new approvals required.

So you’re not just giving a dendritic cell vaccine, you’re programming it.

This allows for layered, sustained immunity, especially when boosters are rotated or combined based on tumor type.

And if you want to understand the type of clinical outcomes this approach can generate 

just look at any of the Mayo Clinic DC vaccine trials.

That’s the benchmark.And under SI 87, it’s now legally executable.

[erg61]

What does this mean for other companies like NWBO. Will they still need to go through trials for safety?